0.00

100.00% -2.0301

After Hours: 2.03 2.03 +

Mural Oncology Plc (MURA)

Overview News Price History Discussions Forecast

Mural Oncology Plc stock is traded at $0.00, with a volume of 0. It is down -100.00% in the last 24 hours and down -100.00% over the past month. Mural Oncology PLC is a clinical-stage oncology company whose entire business is focused on discovering and developing immunotherapies that may meaningfully improve the lives of patients with cancer. By leveraging its core competencies in immune cell modulation and protein engineering, It has developed a portfolio of novel, investigational cytokine therapies designed to address areas of unmet need for patients with a variety of cancers. Its product candidate, Nemvaleukin is an investigational, engineered interleukin-2 cytokine designed to capture and expand the therapeutic benefits of high-dose recombinant human IL-2 while mitigating its hallmark toxicities.

Previous Close:

$2.0301

Open:

24h Volume:

Relative Volume:

0.00

Market Cap:

$35.38M

Revenue:

Net Income/Loss:

P/E Ratio:

EPS:

Net Cash Flow:

1W Performance:

-100.00%

1M Performance:

-100.00%

6M Performance:

-100.00%

1Y Performance:

-100.00%

1-Day Range:

$0.00

1-Week Range:

$0.00

52-Week Range:

$0.00

$4.74

Mural Oncology Plc Stock (MURA) Company Profile

Name

Mural Oncology Plc

Sector

Healthcare (1123)

Industry

Biotechnology (627)

Phone

353 1 905 8020

Address

10 EARLSFORT TERRACE, DUBLIN 2

Employee

116

Twitter

Next Earnings Date

2025-05-20

Latest SEC Filings

MURA's Discussions on Twitter

Compare MURA with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
MURA Mural Oncology Plc	0.00	35.38M	0	0	0	0.00
VRTX Vertex Pharmaceuticals Inc	452.04	113.14B	11.74B	3.68B	3.34B	14.19
REGN Regeneron Pharmaceuticals Inc	741.29	78.49B	14.25B	4.58B	3.88B	41.77
ARGX Argen X Se Adr	877.94	54.76B	3.06B	1.28B	447.35M	19.67
ALNY Alnylam Pharmaceuticals Inc	397.55	54.51B	3.21B	43.57M	221.36M	0.2405
INSM Insmed Inc	197.01	41.64B	447.02M	-1.18B	-906.14M	-6.1812

Mural Oncology Plc Stock (MURA) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Mar-25-25	Downgrade	Morgan Stanley	Overweight → Equal-Weight
Mar-25-25	Downgrade	Raymond James	Strong Buy → Outperform
Jun-28-24	Initiated	Rodman & Renshaw	Buy
Apr-04-24	Initiated	Morgan Stanley	Overweight

Mural Oncology Plc Stock (MURA) Latest News

Dec 12, 2025

XOMA Royalty completes acquisition of Mural Oncology for $2.035 per share - Investing.com Nigeria

Dec 06, 2025

XOMA Royalty completes acquisition of Mural Oncology By Investing.com - Investing.com Nigeria

Dec 06, 2025

Dec 05, 2025

Xoma Completes Acquisition of Mural Oncology - TipRanks

Dec 05, 2025

Mural Oncology Announces Effectiveness of Scheme of Arrangement and Completion of Acquisition - Research Tree

Dec 05, 2025

Xoma Royalty announces closing of transaction to acquire Mural Oncology plc - marketscreener.com

Dec 05, 2025

XOMA Royalty Corporation Completes Acquisition of Mural Oncology plc Under Irish High Court Sanctioned Scheme - Quiver Quantitative

Dec 05, 2025

Mural Oncology Plc Completes Acquisition by XRA 5 Corp. - TipRanks

Dec 05, 2025

XOMA Royalty Announces Closing of Transaction to Acquire Mural Oncology plc - Yahoo Finance

Dec 05, 2025

XOMA Royalty completes acquisition of Mural Oncology - Investing.com India

Dec 05, 2025

Mural Oncology plc Announces Effective Date of Scheme Arrangement for Acquisition by XOMA Royalty Corporation - Quiver Quantitative

Dec 05, 2025

Mural Oncology (Nasdaq: MURA) scheme with XOMA unit effective as Nasdaq listing ends - Stock Titan

Dec 05, 2025

Dec 04, 2025

Mural Oncology plc(NasdaqGM: MURA) dropped from S&P TMI Index - marketscreener.com

Dec 04, 2025